Fiche centre
MedStar Georgetown University Hospital
Washington D.C. — United States
Essais liés11clinical trials
VilleWashington D.C.localisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05691478
Essais cliniques associés
11| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Biospecimen Collection | Cancer | Phase 3 | NCT06337318 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | RECRUITING |
| Bone Scan | Cancer | Phase 2/3 | NCT05691478 | A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | SUSPENDED |
| Biospecimen Collection | Cancer | Phase 3 | NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | RECRUITING |
| bemdaneprocel | Parkinson | Phase 3 | NCT06944522 | exPDite-2 — A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease | RECRUITING |
| Biospecimen Collection | SEP | Phase 1 | NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | RECRUITING |
| Biospecimen Collection | Cancer | Phase 2/3 | NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | RECRUITING |
| Biopsy Procedure | Cancer | Phase 1 | NCT07147231 | Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer | RECRUITING |
| Ocrelizumab | SEP | Phase 4 | NCT05285891 | AMS05 — Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| APL-130277 | Parkinson | Phase 3 | NCT02542696 | Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease | COMPLETED |
| Bevacizumab | Cancer | Phase 2 | NCT00861705 | Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery | COMPLETED |